Quince Therapeutics (QNCX) Exchange Rate Effect (2021 - 2026)
Quince Therapeutics (QNCX) posted quarterly Exchange Rate Effect of -$1.5 million for Q1 2026, down 935.43% year-over-year from $175000.0 in Q1 2025, and down 447.57% quarter-over-quarter from -$267000.0 in Q4 2025.
Quince Therapeutics (QNCX) Exchange Rate Effect (2021 - 2026) Analysis & Trends
Quince Therapeutics' Exchange Rate Effect history runs 6 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 935.43% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$1.8 million (down 1923.96% YoY), while the FY2025 annual figure was -$114000.0, down 149.35% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$1.5 million, down from -$267000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $409000.0 in Q3 2022, with the low at -$1.5 million in Q1 2026.
- The 5-year median for Exchange Rate Effect is -$41000.0 (2025), against an average of -$63588.2.
- The sharpest annual moves came in 2022 and 2026: Exchange Rate Effect jumped 1310.34% in 2022, then slumped 935.43% in 2026.
- Quince Therapeutics' Exchange Rate Effect stood at -$43000.0 in 2022, then sank by 479.07% to -$249000.0 in 2023, then surged by 189.16% to $222000.0 in 2024, then plunged by 220.27% to -$267000.0 in 2025, then plunged by 447.57% to -$1.5 million in 2026.
- Business Quant data shows QNCX's Exchange Rate Effect at -$1.5 million in Q1 2026, -$267000.0 in Q4 2025, and -$41000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -229,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | -267,000.00 |
| Dec 31, 2025 | -267,000.00 |
| Sep 30, 2025 | -41,000.00 |
| Sep 30, 2025 | -41,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -241,000.00 |
| Jun 30, 2024 | -241,000.00 |
| Mar 31, 2024 | 310,000.00 |
| Mar 31, 2024 | 310,000.00 |
| Dec 31, 2023 | -249,000.00 |
| Dec 31, 2023 | -249,000.00 |